Company Information
- Type:
- SME
- Country:
- Germany
- Sector:
- Pharmaceuticals & Biotechnology
- Ownership:
- Privately Held
- Global Compact Status:
- Active
- Participant Since
- 05 May 2014 Letter of Commitment
- Next Communication on Progress (COP) due on:
- 31 July 2024
Communication On Progress
| Published On | Title | Level/Status |
|---|---|---|
| 16-Jun-2023 | 2023 Communication on Progress | Submitted |
| 05-May-2022 | Optima Pharma Sustainability Report | Active |
| 07-May-2021 | Optima - Sustainability Report 2021 | Active |
| 08-May-2020 | Optima - Sustainability Report 2020 | Active |
| 08-May-2019 | Optima - Sustainability Report 2019 | Active |
| 08-May-2018 | Optima - Sustainability Report 2018 | Active |
| 08-May-2017 | Optima - Sustainability Report 2017 | Active |
| 06-May-2016 | Sustainability Report 2015 / UNGC COP | Active |
| 05-May-2015 | Sustainability Report 2015 / UNGC COP | Active |
Note: Responsibility for the content of participants' public communication related to the Ten Principles of the UN Global Compact and their implementation lies with participants themselves and not with the UN Global Compact.
Note on levels: Not applicable refers to the period when the Communication on Progress (CoP) did not require differentiation levels. With the new CoP, for the 2022 Early Adopter Programme, and for 2023, there will be no differentiation levels.